Davis Polk advised the joint lead book-running managers and representatives of the several underwriters in connection with a $110.5 million SEC-registered common stock offering by Revance Therapeutics, Inc. The common stock is listed on the Nasdaq Global Market under the symbol “RVNC.”

Based in Newark, California, Revance Therapeutics is a specialty biopharmaceutical company developing botulinum toxin products for use in aesthetic and therapeutic indications.

The Davis Polk corporate team included partners Bruce K. Dallas and Emily Roberts and associates Beth LeBow and Kimberly Wang. The tax team included partner Rachel D. Kleinberg and associate Adam R. Brownstone. The intellectual property and technology team included partner Pritesh P. Shah and associate Jay Frankel. Members of the Davis Polk team are based in the Northern California and New York offices.

Copy link to share post